Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Msci Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.3 (market cap $12.58B), while Msci Inc trades at $565.2 (market cap $40.38B). The key difference: Msci Inc is far larger — about 3.2× Halozyme Therapeutics Inc. Common Stock's market cap, and Msci Inc pays a 1.48% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Msci Inc for 82 Days on average.
| HALO | MSCI | |
|---|---|---|
Market Cap | $12.58B | $40.38B |
Volume | 2,179,278 | 414,140 |
Sector | Health | Financials |
52-Week High | $115.22 | $643.83 |
52-Week Low | $61.63 | $511.84 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $14.49B | $46.54B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MSCI trades at $565.05, up 1.74% on the day, with a neutral technical signal and key resistance near $567. The company reported Q2 2026 earnings of $4.94 per share, slightly missing estimates, but maintains strong fundamentals with 40.73% net income margin and revenue growth to $3.13 billion in 2025. Recent news includes the completion of the First Street acquisition and upcoming Q3 2026 earnings call.
The outlook is supported by high analyst bullishness (74% buy ratings) and a consensus price target of $701.71, implying significant upside. Risks include high valuation multiples (P/E 30.37) and substantial long-term debt of $4.51 billion. Earnings growth and execution on strategic acquisitions are critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
